Aralez to Ring Closing Bell at Nasdaq on February 16, 2016

MILTON, Ontario, Feb. 12, 2016 /CNW/ -- Aralez Pharmaceuticals Inc. (Nasdaq: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced the Company will ring the Nasdaq Closing Bell at the Nasdaq MarketSite in Times Square, New York at 4:00 p.m. ET on Tuesday, February 16, 2016 to celebrate the formation of Aralez.

Chief Executive Officer, Adrian Adams, will perform the honorary bell ringing ceremony that will be held 3:50 to 4:00 p.m. ET.  A live webcast will be available at: Members of the Aralez Board of Directors and Executive Leadership Team will join in the ceremony.

"We look forward to ringing the Nasdaq Closing Bell to celebrate the strategic formation of Aralez, a new global specialty pharmaceutical company," said Adrian Adams, Chief Executive Officer of Aralez. "Today is also important in that we recently listed and commenced trading on Nasdaq under the ticker symbol ARLZ. This is an exciting time for Aralez and we believe that we are well positioned to deliver growth and to build long-term shareholder value."

About Aralez Pharmaceuticals Inc.
Aralez Pharmaceuticals Inc. (Nasdaq: ARLZ and TSX: ARZ) is a global specialty pharmaceutical company focused on delivering meaningful products to improve patients' lives while focusing on creating shareholder value by acquiring, developing and commercializing products primarily in cardiovascular, pain and other specialty areas. Aralez's Global Headquarters is in Ontario, Canada, the US Headquarters is planned to be in Princeton, NJ and the Irish Headquarters is in Dublin, Ireland. More information about Aralez can be found at

Cautionary Language Concerning Forward-Looking Statements
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:
This press release contains forward-looking statements under applicable securities laws, including, but not limited to, statements related to Aralez being well positioned to deliver growth and to build long-term shareholder value.  These forward-looking statements are based on Aralez's current assumptions and expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the combined company meeting the listing requirements on NASDAQ and TSX and those risks relating to the transaction and the combined  business of POZEN, Tribute and Aralez detailed from time-to-time under the caption "Risk Factors" and elsewhere in each company's respective filings and reports with the SEC. The parties undertake no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events or changes in their expectations.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information:
Aralez Pharmaceuticals Inc.
Nichol Ochsner
Executive Director,
Investor Relations & Corporate Communications

SOURCE Aralez Pharmaceuticals Inc.

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890